

Prolgolimab

Cat. No.:	HY-P99807
CAS No.:	2093956-19-3
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Prolgolimab (BCD-100) is a human IgG1 anti-PD-1 monoclonal antibody containing the Fc-silencing 'LALA' mutation. Prolgolimab can be used for the research of advanced melanoma ^[1] .
IC₅₀ & Target	PD-1 ^[1]
In Vitro	Prolgolimab is an IgG1 anti-PD-1 mAb that contains the Fc-silencing LALA mutation, which provides an immunopotentiating advantage by abolishing the interaction between the Fc region of the antibody and FcγR expressed on various immune cells, thus blocking the possible effector functions of the antibody ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Tjulandin S, et, al. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice. Eur J Cancer. 2021 May;149:222-232.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA